Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION The Summit theme “unlocking the $1 Trillion Wealth ...

Discover BioVie's latest clinical advancements in Parkinson's, long COVID, and ascites. Learn about investment potential and upcoming data readouts.

BioVie Inc. - Special CallCompany ParticipantsCuong Viet Do - President, CEO & DirectorConference Call ParticipantsCraig ...

The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays ...

A single-step high-pressure industrial process replaces complex irradiation methods, producing quantum-grade nanodiamonds ...

A nonbiologic oral IL-23 inhibitor is more effective and safer than an approved oral JAK inhibitor for moderate-to-severe ...

The data aren’t definitive, but continuing OAC or switching to another drug doesn’t seem to be enough for this high-risk ...

The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, ...

First investigational allogeneic pluripotent stem cell derived therapy pivotal Phase III clinical trial exPDite-2 with bemdaneprocel started Phase II gene therapy trial REGENERATE-PD with AB-1005 ...

A popular device used to track personal belongings and ostensibly protect consumers from theft could expose significant ...

Medicus Pharma (MDCX) announced feedback from Type C meeting with United States Food and Drug Administration. The purpose of the Type C meeting ...